Myrexis

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Myrexis sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

Myrexis: 12 sponsored US clinical trials, none currently recruiting.

Myrexis sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 3 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glioblastoma Multiforme, with 1 trials.

Top-decile sponsor footprint

Myrexis ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 27/100

9 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 2

Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme

NCT01285414
TERMINATED Phase 2

A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy

NCT01026727
COMPLETED Phase 1

Safety Study of MPC-3100 in Cancer Patients Who Have Failed Other Treatments

NCT00920205
COMPLETED Phase 2

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

NCT00892931
COMPLETED Phase 2

A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days

NCT01097070
COMPLETED Phase 1

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

NCT00609011
TERMINATED Phase 3

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

NCT00380276
TERMINATED Phase 3

Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

NCT00322036
COMPLETED Phase 2

Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*

NCT00511368
COMPLETED Phase 1

Multiple Dose Study of MPC-6827 in Subjects With Refractory Brain Metastases

NCT00393965
COMPLETED Phase 1

Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

NCT00394446
COMPLETED Phase 3

Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

NCT00105547

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5
Phase 3 3

Therapeutic Areas

Glioblastoma Multiforme 1
Cancer 1

How the Myrexis early-phase archive is shaped

12 indexed studies, none listed as recruiting (0% open); 9 completed (75%).

Phase mix: 3 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Glioblastoma Multiforme (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Myrexis: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Myrexis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share MyrexisAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Myrexis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Myrexis sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Myrexis page

12 registered trials is a research-attention snapshot, not an endorsement of Myrexis or any single study.

  • None of Myrexis's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Glioblastoma Multiforme is the condition Myrexis studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glioblastoma Multiforme trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Myrexis pipeline card: 12 registered trials from official public datasets.Report a data error.